Navigation Links
Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Date:1/15/2014

ed by an additional four weeks of open label treatment, the results of which are not yet available.  The trial enrolled 17 patients with genetically confirmed PWS, including 11 women and 6 men, with a mean age of 33.9 years, and mean body mass index (BMI) of 31.4 kg/m2.  Beloranib appeared to be safe and very well-tolerated.  All 17 patients completed the randomized treatment part of the trial and all opted to continue into and completed the four-week open label extension.

About Prader-Willi Syndrome
Prader-Willi syndrome (PWS), the most common known genetic cause of life-threatening obesity, causes constant hunger that drives PWS patients to gain more weight on fewer calories than the average person.  As a result, many of those affected become morbidly obese before the age of five.  There is currently no cure for this disease.  Although the cause is complex, it results from a deletion or loss of function of a cluster of genes on the 15th chromosome.  PWS typically causes low muscle mass and function, short stature, incomplete sexual development, and a chronic feeling of hunger that, coupled with a metabolism that utilizes drastically fewer calories than normal, can lead to excessive eating and life-threatening obesity.  PWS occurs in males and females equally and in all races, with the same incidence around the world.  Prevalence estimates have ranged from 1:8,000 to 1:50,000 with the most likely figure being approximately 1:40,000.  To the best of our knowledge, prevalence is about 5,000-7,000 people in the United States needing treatment.  You can learn more through the Prader-Willi Syndrome Association website at www.pwsausa.org.

About Beloranib
Beloranib is the first compound in its class that works by targeting a key enzyme called MetAP2 that controls the production and utilization of fatty acids.  Inh
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
4. Zafgen Secures $45 Million in Series E Financing
5. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015  BC Technical, the nation,s leading ... Eclipse Systems, a Nuclear Imaging service company providing ... of their ongoing vision to provide the best, ... BC Technical continues to expand their reach and ... add valuable resources and knowledge in addition to ...
(Date:3/2/2015)... 2, 2015  DURECT Corporation (Nasdaq: ... and the successful completion of a Phase 1 ... DUR-928.  DUR-928 is an endogenous, small-molecule, new chemical ... metabolic diseases such as nonalcoholic fatty liver disease ... organ injuries such as acute kidney injury (AKI).  ...
(Date:3/2/2015)... GERMANTOWN, Md., March 2, 2015  Intrexon Corporation ... synthetic biology, today announced its fourth quarter and ... Business Highlights and Recent Developments: , Acquired ... a new frontier in cellular therapeutics and other ... molecular engineering of food-grade microbes ( Lactococcus lactis ...
Breaking Medicine Technology:BC Technical Acquires Eclipse Systems 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24
... N.J., April 12, 2011 Novartis Pharmaceuticals Corporation ... Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) ... treatment of patients with advanced neuroendocrine tumors (NET) ... provided after presentation of data from the everolimus ...
... 2011 Havel,s market leading EchoStim® Echogenic Insulated ... to perform Peripheral Nerve Blocks (PNBs) using nerve ...  The new improved needle has more, brighter, easier ... giving even inexperienced practitioners the benefits of using ...
Cached Medicine Technology:Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10
(Date:3/2/2015)... This year, the National Multiple Sclerosis Society’s ... opportunities for people across the country to unite, raise ... MS live their best lives. MS Awareness Week is a ... to join the Society’s vision of a world free of ... disease of the central nervous system, interrupts the flow of ...
(Date:3/2/2015)... 2015 Dinner preparation and meal ... the success of DinnerDork , a company ... delicious for thousands of busy customers. The company ... expanding to offer a total of 6 diverse ... appropriate classic recipes and comfort foods; Paleo Palette, ...
(Date:3/2/2015)... 2015 Four Seasons Resort Maui at Wailea, ... anniversary this year, having officially opened its doors on March ... is honoring over 70 employees who started on Day 1 ... the approximately 400 original employees. The celebration will be ... , This Four Seasons flagship resort, the first ...
(Date:3/2/2015)... CA (PRWEB) March 02, 2015 A true ... Eadon, leader of the 1960s cult rock band Khazad Doom, ... by his determination to persevere despite all odds. His motto ... no matter what situation or goal was before him. And ... ’60s, is now being passed on to a new generation. ...
(Date:3/2/2015)... 02, 2015 What are the best ... request references? When are interviews scheduled, how can physicians ... Both training and practicing physicians who are looking for ... and more at the PracticeLink Physician Career Advancement Workshop ... Job Fair is from 5:30 to 8:30 p.m. at ...
Breaking Medicine News(10 mins):Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 3Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 3Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2
... Demonstrated in Favorable Response Rates and Hearing PreservationSUNNYVALE, ... ARAY ), a global leader in the ... data using the CyberKnife(R) Robotic Radiosurgery System was ... Association of Neurological Surgeons (AANS) Annual Meeting, May ...
... Health Organization says a Swine Flu pandemic is now ... experts believe the Federal government will declare a disaster ... the public will become increasing intense as news coverage ... defense: to prepare your department to the highest level ...
... ULURU Inc. (NYSE AMEX: ULU ) announced ... Dressing has been published in the respected peer-reviewed publication, ... is the first peer-review publication detailing clinical experience using ... scientists working at Southern Arizona Limb Salvage Alliance ("SALSA") ...
... Cellular Therapy (ISCT) Demonstrating Potential to Expand Cord ... Fla., May 5 /PRNewswire-FirstCall/ -- Cryo-Cell ... showing that adding menstrual blood stem cells (MenSCs) ... the number of progenitor cells (cells that grow ...
... Health Programs Supported by a Grant from Otsuka ... the quality of care and increasing awareness of ... minority communities are all values held by the ... Awards for Advancing Minority Mental Health.The awards, presented ...
... Holdings, Inc. (OTC Bulletin Board: INHI; INHIW; INHIU), ... associated clinical services, today announced financial results and provided ... 31, 2009.Mr. Steve Watkins, chief executive officer, commented, "We ... of 2009, despite a nationwide shortage of Leucovorin, a ...
Cached Medicine News:Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 2Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 3Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 4Health News:Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications 5Health News:Ready or Not - Flu Pandemic Has Arrived 2Health News:ULURU Inc. Announces Altrazeal(TM) Clinical Experience Published in the International Wound Journal 2Health News:ULURU Inc. Announces Altrazeal(TM) Clinical Experience Published in the International Wound Journal 3Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 2Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 3Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 4Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 5Health News:American Psychiatric Foundation Names 2009 Recipients of Awards for Advancing Minority Mental Health 2Health News:American Psychiatric Foundation Names 2009 Recipients of Awards for Advancing Minority Mental Health 3Health News:American Psychiatric Foundation Names 2009 Recipients of Awards for Advancing Minority Mental Health 4Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 2Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 3Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 4Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 5Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 6Health News:InfuSystem Holdings Reports $9.2 Million of Revenue and 45% Increase in Adjusted EBITDA for the First Quarter of 2009 7
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Latex agglutination test for the qualitative and semiquantitative determination of rheumatoid factor in serum....
RFScan Latex Test Kit-100...
... SYNCHRON CX4 Delta Specialty / Drug ... analyzer that can consolidate Drugs of ... such as thyroid, HbA1c and lipids ... Delta offers a level of automation ...
Medicine Products: